Polaryx Therapeutics annual return on equity
2024
2025
Polaryx Therapeutics Return on Equity (ROE) Growth & History (PLYX)
Polaryx Therapeutics's return on equity was −193.70% for fiscal 2025.
View full Polaryx Therapeutics company overviewPolaryx Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −193.70% | +820.02 pp |
| 2024 | 2024-12-31 | −1,013.73% | — |
Polaryx Therapeutics quarterly return on equity
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −20.56% | +6.32 pp |
| Q1 2026 | 2026-03-31 | −72.14% | +40.57 pp |
| Q4 2025 | 2025-12-31 | −30.31% | — |
| Q3 2025 | 2025-09-30 | −33.46% | — |
| Q2 2025 | 2025-06-30 | −26.88% | — |
| Q1 2025 | 2025-03-31 | −112.70% | — |
Polaryx Therapeutics return on equity trends
Between the periods ended 2024-12-31 and 2025-12-31, Polaryx Therapeutics's return on equity increased from −1,013.73% to −193.70%, a change of +820.02 percentage points. The latest reported quarter, Q2 2026, shows −20.56%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Polaryx Therapeutics source filings ↗